Gege Gui

PhD student at @jhubiostat

[Chris Hourigan @DrChrisHourigan]

Genuinely excited to be finally able to fully share the first major output from the MEASURE consortium at #ASH25 #ASH2025 - the largest cohort of paired tumor and remission WGS from patients with AML https://t.co/2WozDIrEtA

[Chris Hourigan @DrChrisHourigan]

https://t.co/MmjMLoUBcB

[Chris Hourigan @DrChrisHourigan]

So proud of our HouriganLab #ASH23 superstar abstract award winners - biostats PhD student ⁦@GegeGui0⁩ (oral on IDH2 MRD tomorrow Sun in sess617 at 9.30am and poster on IDH1 MRD on Mon) and medical student ⁦⁦@hegdepranay1⁩ presenting TKD MRD poster tomorrow (Sun).

[Chris Hourigan @DrChrisHourigan]

She crushed it! First major international talk for ⁦@GegeGui0⁩ - biostatistics PhD student and key member of staff in Hourigan lab. The first, but not the last, time for her talking at ASH. ⁦@TheBethesdaLabs⁩ ⁦@CIBMTR⁩ ⁦@ASH_hematology⁩

[Chris Hourigan @DrChrisHourigan]

Cleveland clinic medical student ⁦@ClevelandClinic⁩ ⁦@hegdepranay1⁩ presenting work he did on FLT3-TKD MRD during a MRSP year in our lab at ⁦@TheBethesdaLabs⁩ ⁦@NIH⁩ ⁦@CIBMTR⁩

[Laura Dillon, PhD, FACMG @LauraWDillon]

Excited to finally share our work published today in JAMA! https://t.co/LkWR5x5eSs

[Chris Hourigan @DrChrisHourigan]

DNA Sequencing to Detect Residual Disease for Acute Myeloid Leukemia https://t.co/8KevMvCkCE via @JAMA_current part of @JAMANetwork

[Chris Hourigan @DrChrisHourigan]

Pre-MEASURE: FLT3-ITD and mutated NPM1 measurable residual disease before allogeneic transplant in adults with AML in first remission https://t.co/yXfeHgQA5T

[AML Hub @AML_Hub]

During #ASCO2022 , the AML Hub spoke with @DrChrisHourigan, @NIH. We asked, Can pre-transplant MRD testing predict patients who are more likely to relapse?

👉 https://t.co/aZof6CmWjF 👈

#AML #AMLsm #leusm #leukemia

[Chris Hourigan @DrChrisHourigan]

AML MRD Testing By NGS Identifies Adults At High Relapse Risk After Allogeneic Transplantation | ASH Clinical News | American Society of Hematology https://t.co/NSjKzemdE4

[Greg Roloff @RoloffGreg]

MRD in AML was previously most useful for papers, not patients. Until now! @DrChrisHourigan moving us into the “getting stuff done era” with this Herculean 1075 pt study of MRD in CR1 heading to SCT. #ASCO #leusm

[Laura Dillon, PhD, FACMG @LauraWDillon]

Excited for @DrChrisHourigan to present our latest results tomorrow at 11:45AM CT from the Pre-MEASURE study at #ASCO2022 examining #MRD in a large cohort of #AML patients prior to transplant. Stick around for the last session! #savingthebest4last https://t.co/LKY6ITj7gS

[AML Hub @AML_Hub]

CONGRESS #ASCO22 | @DrChrisHourigan @NIH discusses MRD testing prior to allo-SCT for pts with AML in first remission in the Pre-MEASURE study. (N=457). NGS-MRD prior to alloHCT in AML CR1 was prognostic. #leusm #leukemia

[Blood Cancer Discovery @BCD_AACR]

From the July issue: Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid #Leukemia from Nonmalignant #ClonalHematopoiesis. #leusm #singlecell @nih_nhlbi @LauraWDillon @DrChrisHourigan
https://t.co/lIvVXZjpeJ

[Gege Gui @GegeGui0]

Excited to share our work @Meg_Goswami Grateful for all the support from co-authors and especially our brilliant and caring mentor @DrChrisHourigan

[Chris Hourigan @DrChrisHourigan]

I’m so proud of @Meg_Goswami and @GegeGui0 for this work. While this was only a small clinical trial they have shown with their strong logic and beautiful science that in AML patients there was no evidence that adding anti-PD1 treatment to HMA resulted in additional benefit.

[Chris Hourigan @DrChrisHourigan]

Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Nonmalignant Clonal Hematopoiesis https://t.co/H1AvfsHBPG

[Chris Hourigan @DrChrisHourigan]

Summary of pre-alloHCT NGS testing in MDS and AML cohorts of @BMTCTN 0901 clinical trial from @TheBethesdaLabs @GegeGui0 @LauraWDillon Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy. https://t.co/8H17vQpdGD

[Chris Hourigan @DrChrisHourigan]

Spending weekend preparing my talk for big pre-tenure external review. Reflecting how proud I am of amazing work my team at https://t.co/F2mgm4JLGq has done over past four years despite Covid19. Fifty publications. Two plenary + 40 other talks. 8 awards. Great post-lab jobs.

[Chris Hourigan @DrChrisHourigan]

Congrats @LauraWDillon @GegeGui0 https://t.co/g12S3sSC1Q @TheBethesdaLabs @BMTCTN

[Chris Hourigan @DrChrisHourigan]

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients with Myelodysplastic Syndrome @BMTCTN @TheBethesdaLabs @nih_nhlbi @JCOPO_ASCO @LauraWDillon @GegeGui0 @DrStevenDevine @horwi001 @BartScott8 @archerdxinc https://t.co/eoh3f6znT3